ArticleCPT: pharmacometrics & systems pharmacology2026
Comprehensive Pathophysiology Repository for PBPK Modeling in Liver Cirrhosis: Quantifying Continuous Disease Progression and Population Variability.
Article in CPT: pharmacometrics & systems pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pharmacokinetics in the Fontan circulation: a multi-organ puzzle.European heart journal. Cardiovascular pharmacotherapy · 2026Review
- Comprehensive Pathophysiology Repository for PBPK Modeling in Liver Cirrhosis: Quantifying Continuous Disease Progression and Population Variability.CPT: pharmacometrics & systems pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver cirrhosis is accompanied by pathophysiological changes. Due to multiple absorption, distribution, metabolism and excretion (ADME)-related pathophysiological alterations, the estimation of the net pharmacokinetics (PK) change in cirrhotic patients is complex. Physiologically based pharmacokinetic (PBPK) modeling is a mechanistic modeling technique that combines knowledge of physiological and drug-related properties and, thereby, allows the prediction of organism-specific drug PK. For the integration of pathophysiological changes into a PBPK model, such changes need to be quantified appropriately. To date, published liver cirrhosis pathophysiology repositories contain only average changes for three distinct disease stages limiting clinical applicability. Therefore, the aim of this study was the development of a repository that (1) describes physiological alterations throughout the body during cirrhosis progression, (2) quantifies both mean changes and population variability, and (3) adds parameters of not yet included changes. For this purpose, data was gathered and processed using a Markov-Chain-Monte-Carlo (MCMC)-based approach that allowed the handling of heterogenous data and information on population variability. The resulting repository, based on 216,609 data points from 68 literature studies and 208,851 patients from the IBM Explorys electronic health records database, encompasses 30 physiological parameters. Integration into a PBPK modeling framework revealed good predictive performance with 96% of all data points for predicted PK parameter ratios lying within a twofold prediction range. In summary, the presented approach provides an advancement in the field of PK modeling in liver cirrhosis patients, possibly facilitating the planning and analysis of clinical studies in these patients and moving towards virtual studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.